Interferon beta-1a biosimilar - Dong-A ST

Drug Profile

Interferon beta-1a biosimilar - Dong-A ST

Alternative Names: DA-3051; IFN-β biosimilar - Dong-A ST; Interferon beta-1a (IFN β-1a) - Dong-A ST

Latest Information Update: 07 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 01 Sep 2010 DA 3051 is available for licensing. www.donga-pharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top